A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer’s Disease: Investigating Structure through Docking Studies
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
c-Jun N-terminal kinase (JNK) plays an important role in cell death caused by various stimuli. Because the isoform JNK3 is mainly expressed in the brain, it is believed to play a pivotal role in various neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), which still lack plausible therapeutics. To develop a novel and selective JNK3 inhibitor, we conducted a decadal review (2011 to 2021) of published articles on JNK inhibitors, particularly those focusing on a structural perspective and docking insights. We observed the structures of three isoforms of JNK, namely holo-proteins and co-crystal structures, with JNK3 inhibitors and summarized the significant structural aspects of selective JNK3 inhibitors as AD therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Superimposition of six crystal structures of JNK1 (PDB ID: 3PZE [26], 2XRW [27], 4QTD [28], 3ELJ [29], 4AWI [30], and 4L7F [31]) by pulling out the top six structures according to their resolution. The ligand is compound 3 docked into JNK3 (PDB 4WHZ [22]). Residue Met108 is shown in grey.](https://figures.cochat.ai/paper-figures/263ebb9d6d6c4134aa50990ade1147d5/a-perspective-on-the-development-of-c-jun-n-terminal-kinase-inhibitors-as-figure-5.jpg)
![Figure 6 Superimposition of the crystal structures of JNK2 (PDB ID: 3E7O [32], 7CML [33], and 3NPC [34]), of which only three are published. The ligand is compound 3 docked into JNK3 (PDB 4WHZ [22]). Residue Met108 is shown in grey.](https://figures.cochat.ai/paper-figures/9c1e68f05ad8401c979201d57b676cda/a-perspective-on-the-development-of-c-jun-n-terminal-kinase-inhibitors-as-figure-6.jpg)
![Figure 7 Superimposition of six co-crystals of JNK3 selected according to resolution (PDB ID: 4WHZ [22], 4W4W [35], 3OY1 [25], 7KSI [23], 6EMH [36], and 6EQ9 [36]). Compound 3 is docked into the active site of JNK3 (PDB ID: 4WHZ [22]). Residue Met146 is shown in grey.](https://figures.cochat.ai/paper-figures/de5425e7f80b4a08807948143821d16e/a-perspective-on-the-development-of-c-jun-n-terminal-kinase-inhibitors-as-figure-7.jpg)
![Figure 8 (a) Leu144 residue in the crystal structure of JNK3 co-crystalized with compound 4 (PDB ID: 3OY1 [25]), and (b) superimposition of the Ile106 residue in the crystal structure of JNK1 (PDB ID: 3PZE [26]) and compound 4 co-crystalized with JNK3.](https://figures.cochat.ai/paper-figures/028da385aac04c97baca4ca64f266ce2/a-perspective-on-the-development-of-c-jun-n-terminal-kinase-inhibitors-as-figure-8.jpg)
![Figure 9 (a) Crystal structure of JNK3 bound to compound 1 (PDB ID: 4WHZ [22]). (b) Protein surface of the hydrophobic pocket is shown in the same JNK3 co-crystal. Residues that interact with compound 1 and comprise selectivity pocket are emphasized in the thin tube.](https://figures.cochat.ai/paper-figures/3396ff1920194caca9359a799b8b3dc1/a-perspective-on-the-development-of-c-jun-n-terminal-kinase-inhibitors-as-figure-9.jpg)
![Figure 10 (a) Crystal structure of JNK3 bound to compound 2 (PDB ID: 7KSK [23]) (b) Protein surface of the hydrophobic pocket is shown at the same co-crystal. Residues that interact with compound 2 and comprise selectivity pocket are emphasized in thin tube.](https://figures.cochat.ai/paper-figures/253f4b07431d4472a7102ff4c40c82e6/a-perspective-on-the-development-of-c-jun-n-terminal-kinase-inhibitors-as-figure-10.jpg)
![Figure 11 (a) Binding mode of compound 3 docked into the structure of JNK3 (PDB ID: 4WHZ [22]). (b) Surface of the hydrophobic pocket in active site is shown at the same docking structure of compound 3. Residues that interact with compound 3 and comprise the selectivity pocket are emphasized in the thin tube.](https://figures.cochat.ai/paper-figures/de484f5e75864ea880b4d29061792878/a-perspective-on-the-development-of-c-jun-n-terminal-kinase-inhibitors-as-figure-11.jpg)
![Figure 12 (a) Binding mode of compound 4 co-crystallized with JNK3 (PDB ID: 3OY1 [25]). (b) Surface of the selectivity pocket in active site is shown in the same co-crystal. Residues that interact with compound 4 and comprise selectivity pocket are emphasized in the thin tube.](https://figures.cochat.ai/paper-figures/b58e58c2bfed46a6843a72918bd613b1/a-perspective-on-the-development-of-c-jun-n-terminal-kinase-inhibitors-as-figure-12.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In AD, c-Jun N-terminal kinase3 (JNK3) activation is closely associated with neuronal damage, amyloid deposition, and the formation of tau tangles.516”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [516]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · cited 2×
“This process inhibit the mTOR pathway and t e representative cell rescue system and induces a tran l tio a block that prevents protein ex ession [14].”
BackgroundDérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412 · cited 1×
“With the rapid aging of the global population, neurodegenerative diseases such as AD have become a major social issue and have a significant impact not only on patients, but also on other individuals around the patients [8,9].”
BackgroundPhosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae
Ficarro, S. B., McCleland, M. L., Stukenberg, P. T., Burke, D. J., Ross, M. M., Shabanowitz, J., Hunt, D. F., & White, F. M. (2002) · Nature Biotechnology · doi:10.1038/nbt0302-301 · Cited by 1,636 · cited 1×
“There are 518 known protein kinases encoded in the human genome, and protein kinases phosphorylate approximately one-third of all proteins [3,4].”
BackgroundThe regulation of protein function by multisite phosphorylation – a 25 year update
Cohen, P. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01712-6 · Cited by 1,136 · cited 1×
“There are 518 known protein kinases encoded in the human genome, and protein kinases phosphorylate approximately one-third of all proteins [3,4].”
BackgroundTHE ENZYMATIC PHOSPHORYLATION OF PROTEINS
Burnett, G., & Kennedy, E. P. (1954) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71184-8 · Cited by 582 · cited 1×
“Protein kinases were discovered more than 65 years ago, but they have been therapeutic targets for less than 30 years [1,2].”
BackgroundThe c-jun kinase/stress-activated pathway: Regulation, function and role in human disease
Johnson, G. L., & Nakamura, K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.12.009 · Cited by 500 · cited 2×
“Next, the activated MAPKK4 and MAPKK7 phosphorylate JNK at two different sites, and the phosphorylated JNK then phosphorylates the N-terminal of c-Jun to induce an apoptotic signal [11].”
BackgroundKinase Drug Discovery – What’s Next in the Field?
Cohen, P., & Alessi, D. R. (2013) · ACS Chemical Biology · doi:10.1021/cb300610s · Cited by 377 · cited 1×
“Along with this approval, research in the field of non-oncology kinase inhibitors became increasingly active [7].”
BackgroundProperties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Roskoski, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105463 · Cited by 335 · cited 1×
“Many researchers in pharmaceutical companies and academia have worked hard in this area, and as a result, 67 small-molecule kinase inhibitor drugs have been approved by the US FDA as of 2021 [5].”
Background
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“516 Hah et al. have conducted in-depth studies on this target, continuously re fi ning and developing several generations of compounds based on the structure of pan-JNK inhibitor 42 , which was identi fi ed through an in-house kinase-focused library screening.”
BackgroundNatural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer’s Disease
Vrabec, R., Blunden, G., & Cahlíková, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054399 · Cited by 53
“portion is expressed in the heart nd testis [44].”
BackgroundJNK Activation in Alzheimer’s Disease Is Driven by Amyloid β and Is Associated with Tau Pathology
Solas, M., Vela, S., Smerdou, C., Martišová, E., Martínez-Valbuena, I., Luquín, M. R., & Ramírez, M. J. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00093 · Cited by 57
Jun, J., Yang, S., Lee, J.-H., Moon, H., Kim, J., Jung, H., Im, D., Oh, Y., Jang, M., Cho, H., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114894 · Cited by 38
Self-citationKhan, Z. U., Carretero‐Rey, M., de León-López, C. A. M., & Navarro‐Lobato, I. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05203-x · Cited by 33
“In some instances, they are depicted outside the nucleus due to space limitations.) disease [149], and reducing the activity of its phosphorylation enzyme, c-Jun N-terminal kinase, is seen as a potential therapeutic strategy for Alzheimer’s disease [150, 151].”
Metadata
- Authors
- Cho, H., & Hah, J.-M.
- Affiliations
- Hanyang University (KR)
- Corresponding author
- Hah, Jung-Mi
- ORCID
- Hah, Jung-Mi
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2021-10-09
- Volume
- 9
- Issue
- 10
- Pages
- 1431
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC8533360
- OpenAlex
- W3205457107
- Cited by
- 27
- References
- 35
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 10 · 2023: 5 · 2022: 4
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (NRF-2020R1A6A1A03042854, NRF-2021R1A2C2007159)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- c-Jun N-terminal kinase, JNK3 inhibitors, Alzheimer's disease, Parkinson's disease, structure-based drug design, molecular docking, JNK isoforms, co-crystal structure, neurodegenerative diseases, selective kinase inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer’s Disease: Investigating Structure through Docking Studies. https://app.cochat.ai/papers/10.3390/biomedicines9101431
- The paper
- Cho, H., & Hah, J.-M. (2021). A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer’s Disease: Investigating Structure through Docking Studies. Biomedicines. https://doi.org/10.3390/biomedicines9101431
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.